Okuda Akiko, Kurokawa Suguru, Takehashi Masanori, Maeda Aika, Fukuda Katsuya, Kubo Yukari, Nogusa Hyuma, Takatani-Nakase Tomoka, Okuda Shujiro, Ueda Kunihiro, Tanaka Seigo
Laboratory of Pathophysiology and Pharmacotherapeutics, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 Nishikiori-kita, Tondabayashi, Osaka, 584-8540, Japan.
Niigata University Graduate School of Health Sciences, 2-746 Asahimachidori, Chuo-ku, Niigata, 951-8518, Japan.
BMC Neurosci. 2017 Jan 17;18(1):14. doi: 10.1186/s12868-016-0333-0.
Poly(ADP-ribose) polymerase 1 (PARP-1), which catalyzes poly(ADP-ribosyl)ation of proteins by using NAD as a substrate, plays a key role in several nuclear events, including DNA repair, replication, and transcription. Recently, PARP-1 was reported to participate in the somatic cell reprogramming process. Previously, we revealed a role for PARP-1 in the induction of neural apoptosis in a cellular model of cerebral ischemia and suggested the possible use of PARP inhibitors as a new therapeutic intervention. In the present study, we examined the effects of PARP inhibitors on neural stem/progenitor cells (NSPCs) of the mouse brain.
PARP-1 was more abundant and demonstrated higher activity in NSPCs than in mouse embryonic fibroblasts. Treatment with PARP inhibitors suppressed the formation of neurospheres by NSPCs through the suppression of cell cycle progression and the induction of apoptosis. In order to identify the genes responsible for these effects, we investigated gene expression profiles by microarray analyses and found that several genes in the p53 signaling pathway were upregulated, including Cdkn1a, which is critical for cell cycle control, and Fas, Pidd, Pmaip1, and Bbc3, which are principal factors in the apoptosis pathway. Inhibition of poly(ADP-ribosyl)ation increased the levels of p53 protein, but not p53 mRNA, and enhanced the phosphorylation of p53 at Ser18. Experiments with specific inhibitors and also shRNA demonstrated that PARP-1, but not PARP-2, has a role in the regulation of p53. The effects of PARP inhibitors on NSPCs were not observed in Trp53 NSPCs, suggesting a key role for p53 in these events.
On the basis of the finding that PARP inhibitors facilitated the p53 signaling pathway, we propose that poly(ADP-ribosyl)ation contributes to the proliferation and self-renewal of NSPCs through the suppression of p53 activation.
聚(ADP - 核糖)聚合酶1(PARP - 1)以NAD为底物催化蛋白质的聚(ADP - 核糖基)化反应,在包括DNA修复、复制和转录在内的多个核事件中起关键作用。最近,有报道称PARP - 1参与体细胞重编程过程。此前,我们揭示了PARP - 1在脑缺血细胞模型中诱导神经细胞凋亡的作用,并提出PARP抑制剂可能作为一种新的治疗干预手段。在本研究中,我们检测了PARP抑制剂对小鼠脑内神经干细胞/祖细胞(NSPCs)的影响。
PARP - 1在NSPCs中比在小鼠胚胎成纤维细胞中更为丰富且活性更高。PARP抑制剂处理通过抑制细胞周期进程和诱导凋亡,抑制了NSPCs形成神经球。为了确定导致这些效应的基因,我们通过微阵列分析研究了基因表达谱,发现p53信号通路中的几个基因上调,包括对细胞周期控制至关重要的Cdkn1a,以及凋亡途径中的主要因子Fas、Pidd、Pmaip1和Bbc3。聚(ADP - 核糖基)化的抑制增加了p53蛋白水平,但不影响p53 mRNA水平,并增强了p53在Ser18位点的磷酸化。使用特异性抑制剂和短发夹RNA(shRNA)的实验表明,PARP - 1而非PARP - 2在p53的调节中起作用。在Trp53基因敲除的NSPCs中未观察到PARP抑制剂对NSPCs的影响,表明p53在这些事件中起关键作用。
基于PARP抑制剂促进p53信号通路这一发现,我们提出聚(ADP - 核糖基)化通过抑制p53激活促进NSPCs的增殖和自我更新。